BridgeBio Pharma

BridgeBio Pharma, Inc. discovers and develops various medicines for genetic diseases. The company has a pipeline of approximately 20 development programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas. Its principal products in development programs include BBP-265, an oral small molecule transthyretin (TTR) for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; BBP-831/infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor to treat FGFR-driven cancers, as well as for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company is also developing BBP-418 for the treatment of limb-girdle muscular dystro